Washington Trust Bank Cut By $873,072 Its Abbvie (ABBV) Position; Transact Technologies (TACT) Sentiment Is 1.63

TransAct Technologies Incorporated (NASDAQ:TACT) Logo

Transact Technologies Inc (TACT) investors sentiment decreased to 1.63 in Q1 2018. It’s down -0.04, from 1.67 in 2017Q4. The ratio turned negative, as 26 hedge funds increased and started new positions, while 16 sold and decreased their stakes in Transact Technologies Inc. The hedge funds in our database now possess: 3.05 million shares, up from 2.88 million shares in 2017Q4. Also, the number of hedge funds holding Transact Technologies Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 10 Increased: 16 New Position: 10.

Washington Trust Bank decreased Abbvie Inc (ABBV) stake by 7.9% reported in 2018Q1 SEC filing. Washington Trust Bank sold 9,288 shares as Abbvie Inc (ABBV)’s stock declined 16.83%. The Washington Trust Bank holds 108,226 shares with $10.24M value, down from 117,514 last quarter. Abbvie Inc now has $140.28 billion valuation. The stock increased 0.24% or $0.22 during the last trading session, reaching $92.65. About 6.79M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since July 1, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 22/03/2018 – ABBV CITES MAGNITUDE OF EFFECT ACROSS MULTIPLE STUDY PARAMETERS; 25/04/2018 – Protocols: AbbVie advances its two star pipeline therapies, filing BLA for risankizumab and posting promising data for upadacitinib $ABBV; 23/03/2018 – S&PGRBULLETIN: ABBVIE RTGS UNAFFECTED BY TRIAL RESULTS; 15/05/2018 – STAT Plus: Pharmalittle: J&J and AbbVie roll back price hike after criticism; FDA to call out companies that thwart generics; 10/04/2018 – Samsung Bioepis may pay 5% of Humira biosimilar sales as royalty to AbbVie, insiders say; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pemb; 23/04/2018 – EUROPEAN MEDICINES AGENCY VALIDATES TYPE Il VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC; 09/04/2018 – Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis; 07/05/2018 – AbbVie’s Mavyret Falls After 1-Wk Rise, Epclusa Advances: Hep-C; 03/05/2018 – Merck: Phase 3 Keynote-407 Trial With Keytruda Met Pre-Specified Secondary Endpoint

The stock increased 4.17% or $0.5 during the last trading session, reaching $12.5. About 9,213 shares traded. TransAct Technologies Incorporated (TACT) has risen 27.22% since July 1, 2017 and is uptrending. It has outperformed by 14.65% the S&P500. Some Historical TACT News: 21/05/2018 – TransAct Expands Restaurant Solutions Product Suite with Debut of AccuSpot at the National Restaurant Association Show 2018; 24/04/2018 – Pinpoint Intelligence Announces Key Industry Expert Hire at ETA’s TRANSACT; 07/03/2018 – TRANSACT Tech New York City to Feature the Latest Payments Authentication Innovation; 13/04/2018 – FITCH SAYS LATEST U.S. SANCTIONS LIKELY TO HAVE PROFOUND EFFECT ON THE DESIGNATED RUSSIAN COMPANIES, WHICH WOULD BE UNABLE TO TRANSACT IN U.S. DOLLARS; 15/05/2018 – TRANSACT: NZX: NZX REPORTS SALE OF FARMERS WEEKLY; 11/04/2018 – iPayment, Inc. Named a Finalist for ISO of the Year Award at TRANSACT 2018; 07/05/2018 – TransAct And Asia Pioneer Entertainment Sign Distribution Agreement for Asia Gaming Market; 07/05/2018 – Asia Pioneer Entertainment Will Also Become a Certified Regional Repair Center for All of TransAct’s Printer Products; 16/03/2018 – JULONG CO LTD 300202.SZ SAYS IT WINS BID TO SELL CURRENCY-RELATED EQUIPMENT TO INDIA’S AGS TRANSACT TECHNOLOGIES LTD; 30/04/2018 – TransAct Technologies Declares Quarterly Cash Dividend of $0.09 Per Share

Analysts await TransAct Technologies Incorporated (NASDAQ:TACT) to report earnings on August, 2. They expect $0.09 earnings per share, down 25.00% or $0.03 from last year’s $0.12 per share. TACT’s profit will be $666,216 for 34.72 P/E if the $0.09 EPS becomes a reality. After $0.09 actual earnings per share reported by TransAct Technologies Incorporated for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

More news for TransAct Technologies Incorporated (NASDAQ:TACT) were recently published by: Miamiherald.com, which released: “A trail of lawsuits and a failed psychic hotline. Meet the Miami man running MoviePass.” on June 28, 2018. Businesswire.com‘s article titled: “Momentum for AccuDate Solutions Continues as TransAct Secures Potential Placement of Terminals at Six New …” and published on June 06, 2018 is yet another important article.

Since January 1, 0001, it had 0 insider purchases, and 2 selling transactions for $202,700 activity.

Punch & Associates Investment Management Inc. holds 0.36% of its portfolio in TransAct Technologies Incorporated for 311,000 shares. North Star Investment Management Corp. owns 99,600 shares or 0.16% of their US portfolio. Moreover, Teton Advisors Inc. has 0.16% invested in the company for 128,100 shares. The Massachusetts-based Cadence Capital Management Llc has invested 0.11% in the stock. Lapides Asset Management Llc, a Connecticut-based fund reported 21,500 shares.

TransAct Technologies Incorporated designs, develops, assembles, and markets transaction and specialty printers and terminals in the United States and internationally. The company has market cap of $92.53 million. It offers thermal, inkjet, and impact printers and terminals to generate food rotation date and nutritional labels, promotional coupons, and transaction records, such as receipts, tickets, register journals, and other documents, as well as for printed logging and plotting of oil field and drilling data. It has a 29.76 P/E ratio. The firm also provides consumable products, including inkjet cartridges, ribbons, receipt papers, color thermal papers, and other printing supplies, as well as replacement parts; maintenance, repair, and testing services; and refurbished printers.

Washington Trust Bank increased Vanguard Etf/Usa (VTI) stake by 3,019 shares to 26,715 valued at $3.63 million in 2018Q1. It also upped Verizon Communications Inc (NYSE:VZ) stake by 9,052 shares and now owns 89,319 shares. Newmont Mining Corp (NYSE:NEM) was raised too.

Among 14 analysts covering AbbVie (NYSE:ABBV), 5 have Buy rating, 2 Sell and 7 Hold. Therefore 36% are positive. AbbVie has $15700 highest and $78 lowest target. $116.18’s average target is 25.40% above currents $92.65 stock price. AbbVie had 28 analyst reports since January 4, 2018 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, April 10. Bank of America maintained AbbVie Inc. (NYSE:ABBV) on Monday, March 26 with “Hold” rating. The firm has “Hold” rating given on Thursday, March 22 by Leerink Swann. The firm has “Underperform” rating by BMO Capital Markets given on Tuesday, January 30. On Monday, January 29 the stock rating was downgraded by Leerink Swann to “Hold”. The firm has “Buy” rating by Jefferies given on Friday, March 23. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Friday, February 2 by Argus Research. The rating was downgraded by PiperJaffray to “Neutral” on Friday, June 1. As per Friday, January 26, the company rating was maintained by Cowen & Co. Bernstein maintained the stock with “Hold” rating in Thursday, March 22 report.

Since February 19, 2018, it had 1 buy, and 10 selling transactions for $26.70 million activity. Michael Robert A. sold $119,351 worth of stock. SEVERINO MICHAEL had sold 2,643 shares worth $311,684 on Wednesday, February 28. SALEKI-GERHARDT AZITA also sold $157,458 worth of AbbVie Inc. (NYSE:ABBV) shares. On Wednesday, June 20 RAPP EDWARD J bought $99,909 worth of AbbVie Inc. (NYSE:ABBV) or 1,013 shares. 18,129 shares valued at $2.15M were sold by RICHMOND TIMOTHY J. on Wednesday, February 28. The insider ALBAN CARLOS sold $9.57 million. $2.95 million worth of AbbVie Inc. (NYSE:ABBV) was sold by Schumacher Laura J.

Investors sentiment decreased to 0.7 in 2018 Q1. Its down 0.10, from 0.8 in 2017Q4. It dropped, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Peapack Gladstone Financial Corp accumulated 157,444 shares or 0% of the stock. Cornerstone Advsr reported 2,897 shares. Jump Trading Ltd Com stated it has 3,389 shares or 0.03% of all its holdings. Sei Invs, a Pennsylvania-based fund reported 461,684 shares. 64,655 are owned by Gyroscope Cap Management Grp Inc Ltd Liability Com. Northeast Fincl Consultants holds 0.09% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 2,920 shares. Cobblestone Advsrs Ltd Liability Co Ny holds 16,055 shares or 0.15% of its portfolio. North Carolina-based Stearns Fincl Services Gp has invested 0.36% in AbbVie Inc. (NYSE:ABBV). Hgk Asset Mgmt reported 6,850 shares or 0.1% of all its holdings. Twin Tree Mgmt Limited Partnership has invested 0.06% in AbbVie Inc. (NYSE:ABBV). 13,115 were reported by Pittenger Anderson. Endurance Wealth Management stated it has 1.4% of its portfolio in AbbVie Inc. (NYSE:ABBV). 35,953 are owned by Canandaigua Financial Bank Tru Co. Bonness Enterprises reported 36,600 shares or 2.41% of all its holdings. Dynamic Advisor Solutions Ltd Liability stated it has 0.76% of its portfolio in AbbVie Inc. (NYSE:ABBV).

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98 billion for 11.76 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

TransAct Technologies Incorporated (NASDAQ:TACT) Institutional Positions Chart